IL13 and Alzheimer disease: Dupilumab and lebrikizumab showed the highest efficacy, suggesting that the IL-13 has the highest contribution in the pathogenesis of AD among the evaluated drug targets, and that baseline IL-13 level could be a potential predictive biomarker to stratify those who respond well to dupilumab.